Prostate cancer, bladder cancer, kidney cancer, ovarian cancer and uterus cancer.
Special clinical interests
Prostate cancer, bladder cancer, kidney cancer, cancer of the ovary, cancer of the uterus, general management of all common cancers.
- International and national clinical trials - evaluating novel agents.
- Assessment of the quality of life of prostate cancer patients.
- Complex radiotherapy planning evaluation.
- ASCO: American Society of Clinical Oncology.
- ESMO: European Society for Medical Oncology.
- AACR: American Association for Cancer Research.
- MASCC: Multinational Association of Supportive Care in Cancer.
- EAU: European Association of Urology.
- ABS: American Brachytherapy Society.
- BOA: British Oncological Association.
- ASTRO: American Society for Therapeutic Radiology and Oncology.
- BUG: British Uro-oncology Group.
- ESTRO: European Society for Therapeutic Radiology and Oncology.
Current NHS post
Consultant Oncologist, Nottingham City Hospital.
Profile of Dr Sundar
Dr Sundar specialises in non-surgical treatment modalities such as chemotherapy, hormone therapy, immunotherapy, molecular targeted therapy, advanced external radiotherapy and radioisotope therapy. Having been trained as a general oncologist, he is quite happy to treat all common cancers.
Dr Sundar likes to see patients promptly and is a firm believer in individualised care. He is very approachable and happy to discuss each and every concern of his patients. He also strongly believes that a focus on the quality of life is very important for all cancer patients.
He has published extensively and presented studies at national and international conferences. He regularly enters patients into national and international clinical trials evaluating new and exciting anti-cancer drugs.
He is on the trial management group of RIB trial (a multicentre randomised trial of single dose radiotherapy compared to ibandronate for localised metastatic bone pain). They presented the results at the European Cancer Conference in Stockholm.
In collaboration with European investigators, the group successfully finished recruitment (sample size 800 pts, personally 44 pts) to a phase 3 multicentre randomised trial in prostate cancer. They presented early toxicity results at the European Cancer Conference in Berlin.
He is collaborating with ASAP research group at the School of Computer Science, University of Nottingham. They have presented the results at various conferences round the world. The full list of publications (journal papers and conference abstracts) is on the University of Nottingham website.
He is recruiting patients to a quality of life study in collaboration with Prof Eamonn Ferguson at the Dept of Psychology at the University of Nottingham. They are validating a new rating scale evaluating the side effects of androgen deprivation therapy. They presented preliminary results at the European Cancer Conference in Stockholm.
More information can be found on his website: http://www.sundar.co.uk.